May 26, 2024Open Access

Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports

Key Points

Key points are not available for this paper at this time.

Abstract

Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Mori et al. (Sun,) studied this question.

synapsesocial.com/papers/68e6859fb6db64358760e7dd https://doi.org/https://doi.org/10.1002/iju5.12736

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma2017 · 3,395 citations
2Prognostic score predicts overall survival following complete urinary tract extirpation2020 · 3 citations
3Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study2000 · 2,287 citations
4Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors2016 · 54 citations
5Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience2019 · 12 citations

AI에게 질문

Bookmark

View Full Paper